Index M

Macular degeneration

dizziness and: Sec. 3, Ch. 20

Mad cow disease

dementia in: Sec. 3 Ch. 27 [sidebar]

Magnesium salts

in constipation: Sec. 3, Ch. 55

Magnesium deficiency: Sec. 3, Ch. 17

Magnet therapy: Sec. 2, Ch. 7

Magnetic resonance angiography

peripheral artery: Sec. 3, Ch. 44

in stroke: Sec. 3, Ch. 28

Magnetic resonance imaging: Sec. 2, Ch. 10

in aortic aneurysm: Sec. 3, Ch. 44

in aortic dissection: Sec. 3, Ch. 44

in breast cancer: Sec. 3, Ch. 51

in clotting disorders: Sec. 3, Ch. 49

in fracture: Sec. 3, Ch. 23

in stroke: Sec. 3, Ch. 28

Malignant tumor: Sec. 3, Ch. 50 (see also Cancer)

Malnutrition: (see Undernutrition)

Mammography: Sec. 2, Ch. 10; Sec. 3, Ch. 51

Managed care: Sec. 4, Ch. 66

Manic depression: Sec. 3, Ch. 32; Sec. 3, Ch. 32; Sec. 3, Ch. 32

information resources on: 885

Manometry

esophageal: Sec. 3, Ch. 54; Sec. 3, Ch. 54

MAOIs (monoamine oxidase inhibitors)

in Parkinson's disease: Sec. 3, Ch. 30; Sec. 3, Ch. 30

Marriage: Sec. 4, Ch. 63

Massage: Sec. 2, Ch. 13

in osteoarthritis: Sec. 3, Ch. 41

Mastectomy: Sec. 3, Ch. 51

Masturbation: Sec. 4, Ch. 63

Medic Alert 887

Medicaid: Sec. 4, Ch. 66

Medical ethicist: Sec. 2, Ch. 9

Medical history: Sec. 2, Ch. 10

form for: Sec. 2, Ch. 8

before surgery: Sec. 2, Ch. 12

Medical record: Sec. 2, Ch. 9

Medicare + Choice: Sec. 4, Ch. 66

Medicare: Sec. 4, Ch. 66

in last year of life: Sec. 1, Ch. 3

Medications: (see Drugs)

Medigap insurance: Sec. 4, Ch. 66

Mediterranean diet: Sec. 1 Ch. 1 [sidebar]

Megestrol: Sec. 3, Ch. 50

Meglitinides: Sec. 3, Ch. 34; Sec. 3, Ch. 34

Melanocytes: Sec. 3 Ch. 35 [detail]; Sec. 1, Ch. 2

Melanoma: Sec. 3, Ch. 51

Melatonin: Sec. 2, Ch. 7

in circadian rhythm disorders: Sec. 3, Ch. 31

in insomnia: Sec. 3, Ch. 31

Memantine: Sec. 3, Ch. 27

Memory aids: Sec. 2, Ch. 6

Memory

in Alzheimer's disease: Sec. 3, Ch. 27

in dementia: Sec. 3, Ch. 27

Meniere's disease: Sec. 3, Ch. 20; Sec. 3, Ch. 20

Menopause: Sec. 1, Ch. 2; Sec. 3, Ch. 58

bone loss after: Sec. 3 Ch. 22 [detail] (see also Osteoporosis)

coronary artery disease after: Sec. 3, Ch. 45

Mental health disorders: Sec. 3, Ch. 32

anxiety: Sec. 3, Ch. 32

depression: Sec. 3, Ch. 32 (see also Depression)

erectile dysfunction in: Sec. 3 Ch. 59 [detail]; Sec. 3 Ch. 59 [sidebar]

information resources on: 885, 888

psychosis: Sec. 3, Ch. 32

Mental status: (see also Confusion)

capacity and: Sec. 4, Ch. 65

hospitalization and: Sec. 2, Ch. 11

testing of: Sec. 3, Ch. 25; Sec. 3, Ch. 27

Meperidine: Sec. 2, Ch. 6

Meprobamate: Sec. 2, Ch. 6

Mesenteric artery: Sec. 3, Ch. 44

Mesoridazine: Sec. 3, Ch. 32

Metastasis: Sec. 3, Ch. 50; Sec. 3, Ch. 50 (see also Cancer)

from breast cancer: Sec. 3, Ch. 51

from colorectal cancer: Sec. 3, Ch. 51

from prostate cancer: Sec. 3, Ch. 51

to lungs: Sec. 3, Ch. 51

treatment of: Sec. 3, Ch. 50

Metaxalone: Sec. 2, Ch. 6

Metered-dose inhaler: Sec. 3, Ch. 53; Sec. 3, Ch. 53

Metformin: Sec. 3, Ch. 34

dye interaction with: Sec. 2, Ch. 10

Methimazole: Sec. 3, Ch. 33

Methocarbamol: Sec. 2, Ch. 6

Methotrexate

medicinal herb interactions with: Sec. 2, Ch. 7

in rheumatoid arthritis: Sec. 3, Ch. 41

Methylcellulose

in constipation: Sec. 3, Ch. 55; Sec. 3, Ch. 55

in diarrhea: Sec. 3, Ch. 55

Methylclothiazide: Sec. 3, Ch. 43

Methyldopa: Sec. 2, Ch. 6

Methylphenidate: Sec. 3, Ch. 32

Metolazone: Sec. 3, Ch. 18

in heart failure: Sec. 3, Ch. 46; Sec. 3, Ch. 46

in high blood pressure: Sec. 3, Ch. 43

Metoprolol

in abnormal heart rhythms: Sec. 3, Ch. 47

in coronary artery disease: Sec. 3, Ch. 45

in heart failure: Sec. 3, Ch. 46

in high blood pressure: Sec. 3, Ch. 43

Mexiletine: Sec. 3, Ch. 47

Midodrine: Sec. 3, Ch. 30

Miglitol: Sec. 3, Ch. 34

Migratory phlebitis (thrombophlebitis): Sec. 3, Ch. 44

Milk intolerance

diarrhea and: Sec. 3, Ch. 55

undernutrition and: Sec. 3 Ch. 17 [detail]

Milk intolerance: Sec. 1, Ch. 2

Milrinone: Sec. 3, Ch. 46

Minerals: Sec. 2, Ch. 5

deficiency of: Sec. 3, Ch. 17; Sec. 3, Ch. 17

dietary

     medicinal herb interactions with: Sec. 2, Ch. 7

in food: Sec. 2, Ch. 5

high doses of: Sec. 3, Ch. 17

Ministroke (transient ischemic attack): Sec. 3 Ch. 28 [sidebar]

driving and: Sec. 4, Ch. 62

Mirtazapine

in depression: Sec. 3, Ch. 32

in insomnia: Sec. 3, Ch. 31

Mistreatment: Sec. 4, Ch. 64

Mitral valve: Sec. 3, Ch. 45; Sec. 3, Ch. 48

regurgitation of: Sec. 3, Ch. 48; Sec. 3, Ch. 48

stenosis of: Sec. 3, Ch. 48; Sec. 3, Ch. 48

Moexipril

in coronary artery disease: Sec. 3, Ch. 45

in heart failure: Sec. 3, Ch. 46

Moisturizers: Sec. 3, Ch. 35

Mole: Sec. 3 Ch. 35 [sidebar]

Molindone: Sec. 3, Ch. 32

Monoamine oxidase inhibitors (MAOIs)

in Parkinson's disease: Sec. 3, Ch. 30; Sec. 3, Ch. 30

Monoclonal antibodies

in multiple myeloma: Sec. 3, Ch. 51

Montelukast: Sec. 3, Ch. 38

Mood stabilizers: Sec. 3, Ch. 32

Moricizine: Sec. 3, Ch. 47

Morphine

in coronary artery disease: Sec. 3, Ch. 45

urinary incontinence with: Sec. 3, Ch. 57

Mortality

causes of: Sec. 1, Ch. 3

Motor nerves: Sec. 3, Ch. 29

Motor vehicle: (see Automobiles; Driving)

Mouth: Sec. 3, Ch. 39

aging-related changes in: Sec. 1, Ch. 2

cancer of: Sec. 3, Ch. 39; Sec. 3, Ch. 51

candidiasis of: Sec. 3, Ch. 39

care for: Sec. 3, Ch. 39

dry: Sec. 1, Ch. 2; Sec. 3, Ch. 39

     after radiation therapy: Sec. 3, Ch. 51

in gastroesophageal reflux: Sec. 3, Ch. 54

sores in: Sec. 3, Ch. 51

     after radiation therapy: Sec. 3, Ch. 51

     at end of life: Sec. 2, Ch. 16

Movement disorders

in dementia: Sec. 3, Ch. 27

during sleep: Sec. 3, Ch. 31

information resources on: 887

physical therapy for: Sec. 2, Ch. 13

in stroke: Sec. 3, Ch. 28

testing safety and: Sec. 2, Ch. 10

MRI: (see Magnetic resonance imaging)

Mucus

in chronic bronchitis: Sec. 3, Ch. 53

in COPD: Sec. 3, Ch. 53; Sec. 3, Ch. 53

in influenza: Sec. 3, Ch. 52

in pneumonia: Sec. 3, Ch. 52; Sec. 3, Ch. 52

Multi-infarct dementia: Sec. 3, Ch. 27

Multiple myeloma: Sec. 3, Ch. 51

Multiple sleep latency test: Sec. 2, Ch. 10

Multivitamin: Sec. 2, Ch. 5; Sec. 3, Ch. 17

Murmurs

in aortic sclerosis: Sec. 3 Ch. 48 [sidebar]

in heart valve disorders: Sec. 3, Ch. 48

Muscle mass

estimate of: Sec. 2, Ch. 5; Sec. 3, Ch. 17

loss of: Sec. 1, Ch. 2; Sec. 2, Ch. 11

Muscle(s)

aging of: Sec. 1, Ch. 2

anal: Sec. 3, Ch. 55

bladder: Sec. 1, Ch. 2

cramps in

     in atherosclerosis: Sec. 3, Ch. 44

electrical stimulation of: Sec. 2, Ch. 13

electromyography of: Sec. 2, Ch. 10

immobilization effects on: Sec. 1, Ch. 2

inflammation of (myositis)

     in influenza: Sec. 3, Ch. 52; Sec. 3, Ch. 52

loss of: Sec. 1, Ch. 2; Sec. 2, Ch. 11

in Parkinson's disease: Sec. 3, Ch. 30

in polymyalgia rheumatica: Sec. 3, Ch. 42

prolonged contractions of (dystonia): Sec. 3, Ch. 30

repetitive movements of: Sec. 3, Ch. 30

rigidity of (progressive supranuclear palsy): Sec. 3, Ch. 30

spasms of: Sec. 3, Ch. 30; Sec. 3, Ch. 31

     treatment of: Sec. 2, Ch. 13

strengthening exercise for: Sec. 2, Ch. 13; Sec. 3, Ch. 60

     in arthritis: Sec. 3, Ch. 60

     after fracture treatment: Sec. 3, Ch. 23

     in Parkinson's disease: Sec. 3, Ch. 60

     after stroke: Sec. 3, Ch. 60

stretching exercise for: Sec. 3, Ch. 60

     in arthritis: Sec. 3, Ch. 60

     in Parkinson's disease: Sec. 3, Ch. 60

weakness of

     bed rest and: Sec. 1, Ch. 2

     in cancer: Sec. 3, Ch. 50

     dizziness and: Sec. 3, Ch. 20

     in postpolio syndrome: Sec. 3, Ch. 29

Myasthenia gravis

swallowing difficulty in: Sec. 3, Ch. 54

Mycobacterium tuberculosis infection: Sec. 3, Ch. 52

Myelodysplastic syndrome: Sec. 3, Ch. 49; Sec. 3 Ch. 49 [sidebar]

Myelofibrosis: Sec. 3, Ch. 49; Sec. 3, Ch. 49; Sec. 3 Ch. 49 [sidebar]

Myeloma

multiple: Sec. 3, Ch. 51

Myeloproliferative disorders: Sec. 3 Ch. 49 [sidebar]

Myocardial infarction: (see Heart attack)

Myocardial ischemia: Sec. 3, Ch. 45

Myoclonus

Myositis: Sec. 3, Ch. 52; Sec. 3, Ch. 52

Myotomy

in achalasia: Sec. 3, Ch. 54

Myxedema coma: Sec. 3, Ch. 33

Myxomatous degeneration: Sec. 3, Ch. 48